Greece's health technology assessment committee for medicines, set up in 2018 under article 247 of Law 4512/2018. It gives its opinion when the insurer is asked to pay for an unlisted medicine in an exceptional case.
The OECD and European Commission's 2025 profile records that health technology assessment was established in Greece in 2018 and is carried out for medicines but not for other health technologies; it concentrates mainly on clinical aspects and less on economic evaluation and the wider value of cancer medicines, partly because of understaffing and administrative barriers, and an initiative to restructure the process around value-based approaches had recently been announced. Law 4931/2022 (Government Gazette A 94, 13 May 2022) names the committee as the Επιτροπή Αξιολόγησης και Αποζημίωσης Φαρμάκων Ανθρώπινης Χρήσης of article 247 of Law 4512/2018 and adds to that article a route by which the insurer's board, after the committee's opinion, may approve in exceptional cases a medicine that is not on the reimbursed list for one patient's course of treatment; the same law applies the committee members' conflict-of-interest rules to the reviewing doctors of the insurer's electronic pre-approval system.
The profile also records that the share of a sample of high-benefit breast and lung cancer indications publicly reimbursed in Greece on 1 April 2023 was 54%, against an EU average of 59%, and that the time from EU authorisation to a reimbursement decision was more than 550 days. Article 247 of Law 4512/2018 itself, which sets out the committee's wider role, was not read. The committee's own decisions and membership were not read either: the Ministry of Health's site did not answer scripts on 11 November 2026 and was not searched for them when it answered on 17 November 2026.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/